• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童重度血友病预防性治疗的经验

Experience of prophylaxis treatment in children with severe haemophilia.

作者信息

Yee T T, Beeton K, Griffioen A, Harrington C, Miners A, Lee C A, Brown S A

机构信息

Haemophilia centre and Haemostasis Unit, Royal Free NHS Trust, UK.

出版信息

Haemophilia. 2002 Mar;8(2):76-82. doi: 10.1046/j.1365-2516.2002.00630.x.

DOI:10.1046/j.1365-2516.2002.00630.x
PMID:11952841
Abstract

The practice of prophylactic treatment of boys with severe haemophilia has been evaluated in our centre. Prophylaxis was started at the median age of 3.7 years (range 0.4-12.7 years) in 38/41 children (93%) under 17 years of age. Median follow-up was 4.1 years (range 0.4-12.7 years). The criteria of primary prophylaxis according to the definition by the European Paediatric Network of Haemophilia Management was fulfilled by 9/38 (24%). Although a majority [76%, 29/38] of the children started prophylaxis after a median number of joint bleeds of 3.5, 70% of the children in this group had clinical joint scores of 0. Intravenous catheter insertion was required at a median age of 15.5 months (range 5-36 months) in 21% of the children, resulting in a catheter infection rate of 1.74 per 1000 catheter days. None developed an inhibitor on prophylaxis and three patients who had low-titre inhibitors (< 5 Bethesda units) prior to prophylaxis had undetectable inhibitors after prophylaxis. The home-treatment training programme required considerable time and cost. As a result, 87% of the children used peripheral venous access and hospital visits declined as prophylaxis became established. Parents' incentives for prophylaxis were that the children undertook many physical activities and sports previously not recommended, there was less parental anxiety and an overall improvement in the quality of life for the whole family.

摘要

我们中心对重度血友病男孩的预防性治疗实践进行了评估。38名17岁以下儿童(占93%,共41名)在3.7岁(范围0.4 - 12.7岁)的中位年龄开始进行预防治疗。中位随访时间为4.1年(范围0.4 - 12.7年)。根据欧洲儿科血友病管理网络定义的初级预防标准,9名(24%)符合要求。虽然大多数儿童(76%,29/38)在关节出血中位数为3.5次后开始预防治疗,但该组70%的儿童临床关节评分为0。21%的儿童在15.5个月(范围5 - 36个月)的中位年龄需要进行静脉导管插入,导管感染率为每1000个导管日1.74例。在预防治疗期间无人产生抑制物,3名在预防治疗前有低滴度抑制物(< 5贝塞斯达单位)的患者在预防治疗后抑制物检测不到。家庭治疗培训计划需要大量时间和成本。结果,87%的儿童使用外周静脉通路,随着预防治疗的建立,住院次数减少。家长支持预防治疗的原因是孩子能够进行许多以前不被推荐的体育活动和运动,家长焦虑减少,整个家庭的生活质量总体提高。

相似文献

1
Experience of prophylaxis treatment in children with severe haemophilia.儿童重度血友病预防性治疗的经验
Haemophilia. 2002 Mar;8(2):76-82. doi: 10.1046/j.1365-2516.2002.00630.x.
2
A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.在单一血友病治疗中心中,对 A 型和 B 型血友病儿童进行传统与加拿大定制预防剂量预防因子输注的比较。
Haemophilia. 2012 Jul;18(4):561-7. doi: 10.1111/j.1365-2516.2011.02741.x. Epub 2012 Jan 5.
3
The overall effectiveness of prophylaxis in severe haemophilia.严重血友病预防治疗的总体疗效。
Haemophilia. 2003 May;9(3):272-8. doi: 10.1046/j.1365-2516.2003.00757.x.
4
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.2663名血友病儿童和成人预防性治疗的应用:2006年加拿大全国血友病预防性治疗调查结果
Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14.
5
When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.血友病A和B患者的预防性治疗应何时开始?——德国的经验。
Haemophilia. 1998 Jul;4(4):413-7. doi: 10.1046/j.1365-2516.1998.440413.x.
6
[Prevention of joint damage in hemophilic children with early prophylaxis].[早期预防对血友病患儿关节损伤的预防作用]
Orthopade. 1999 Apr;28(4):341-6. doi: 10.1007/PL00003616.
7
Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.重度血友病的预防:有无抑制物情况下的临床挑战
Haemophilia. 2008 Jul;14 Suppl 3:196-201. doi: 10.1111/j.1365-2516.2008.01736.x.
8
Optimizing factor prophylaxis for the haemophilia population: where do we stand?优化血友病患者的因子预防治疗:我们目前的状况如何?
Haemophilia. 2004 Oct;10 Suppl 4:97-104. doi: 10.1111/j.1365-2516.2004.00998.x.
9
Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.重度血友病的预防性治疗与按需治疗策略:成本与长期结果的比较
Haemophilia. 2002 Nov;8(6):745-52. doi: 10.1046/j.1365-2516.2002.00695.x.
10
Prophylaxis for severe haemophilia: clinical and economical issues.重度血友病的预防:临床与经济问题
Haemophilia. 2003 Jul;9(4):376-81. doi: 10.1046/j.1365-2516.2003.00764.x.

引用本文的文献

1
Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A.一级预防对重度甲型血友病患者关节状态的长期影响。
Res Pract Thromb Haemost. 2023 Jan 12;7(1):100005. doi: 10.1016/j.rpth.2022.100005. eCollection 2023 Jan.
2
Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B.用于治疗B型血友病的延长半衰期重组凝血因子IX产品的临床试验数据更新
Ther Adv Hematol. 2018 Oct 5;9(11):335-346. doi: 10.1177/2040620718802606. eCollection 2018 Nov.
3
Recent advances in hemophilia B therapy.
乙型血友病治疗的最新进展。
Drug Deliv Transl Res. 2017 Jun;7(3):359-371. doi: 10.1007/s13346-017-0365-8.
4
New treatments in hemophilia: insights for the clinician.血友病的新治疗方法:临床医生的见解。
Ther Adv Hematol. 2012 Jun;3(3):165-75. doi: 10.1177/2040620712440007.
5
Treatment of hemophilia: a review of current advances and ongoing issues.血友病的治疗:当前进展与现存问题综述
J Blood Med. 2010;1:183-95. doi: 10.2147/JBM.S6885. Epub 2010 Aug 30.
6
Need for Prophylactic Treatment in Adult Haemophilia A Patients.成人甲型血友病患者预防性治疗的必要性。
Transfus Med Hemother. 2009;36(4):283-288. doi: 10.1159/000225965. Epub 2009 Jul 10.
7
Primary prophylaxis in children with haemophilia.血友病患儿的初级预防。
Blood Transfus. 2008 Sep;6 Suppl 2(Suppl 2):s4-11. doi: 10.2450/2008.0030-08.